{"DataElement":{"publicId":"6690683","version":"1","preferredName":"Ovarian Cancer Additional Pathologic Finding Other Specify","preferredDefinition":"Text term that represents other significant pathologic finding present in a patient with ovarian cancer not previously listed.","longName":"OVAR_ADD_PATH_SPEC","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"6690577","version":"1","preferredName":"Ovarian Carcinoma Additional Pathologic Finding Identification","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms._Added; extra; further._Caused by or altered by or manifesting disease or pathology._Clinical, laboratory or molecular evidence, or absence of evidence of disease._The procedure of having an identity established.","longName":"3304105v1.0:6423721v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3304105","version":"1","preferredName":"Ovarian Carcinoma","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms. --2002","longName":"C4908","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1C9C115-8BEA-6AED-E040-BB89AD43131A","latestVersionIndicator":"Yes","beginDate":"2011-11-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-15","modifiedBy":"ONEDATA","dateModified":"2011-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6423721","version":"1","preferredName":"Additional Pathologic Finding Identification","preferredDefinition":"Added; extra; further.:Caused by or altered by or manifesting disease or pathology.:Clinical, laboratory or molecular evidence, or absence of evidence of disease.:The procedure of having an identity established.","longName":"C25406:C25610:C3367:C25737","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Finding","conceptCode":"C3367","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identification","conceptCode":"C25737","definition":"The procedure of having an identity established.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7520AF04-2EDF-0973-E053-F662850AC1CF","latestVersionIndicator":"Yes","beginDate":"2018-09-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-09-05","modifiedBy":"ONEDATA","dateModified":"2018-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86447D1A-7772-53AC-E053-F662850ABD54","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-11","modifiedBy":"HARTLEYG","dateModified":"2019-04-17","changeDescription":"Curated to support Ovarian content","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2666713","version":"2","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"132D4785-528E-5337-E050-BB89AD433CA8","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2015-04-07","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"7/19/17 jk transferred context and added registration status, CSI per Round 5 finalization task. 4/28/15 released. jc  4/7/15 VD versioned per COG WG: inc to 100 char, remove min limit, chg concept domain to assessment result. jc 1/25/13 added ACRIN Old caBIG CSI.  3/21/12 - changed origin from IVI to ACRIN.  3/5/08 - released for UoWASH FES CRF.   7/23/07-created for ACRIN PET CDEs","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000168","version":"1","longName":"Ovarian","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify additional pathologic","type":"Preferred Question Text","description":"Specify additional pathologic findings","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86448DEA-377A-5AC4-E053-F662850A7321","latestVersionIndicator":"Yes","beginDate":"2019-04-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-11","modifiedBy":"HARTLEYG","dateModified":"2019-04-17","changeDescription":"Curated to support Ovarian content","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}